Ligand News and Research

RSS
Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Ligand Pharmaceuticals receives $1 million as payment from N. V. Organon

Ligand Pharmaceuticals receives $1 million as payment from N. V. Organon

Ligand Pharmaceuticals acquires Neurogen

Ligand Pharmaceuticals acquires Neurogen

GSK receives European CHMP positive opinion for Revolade

GSK receives European CHMP positive opinion for Revolade

Neurogen receives listing compliance notice letter from NASDAQ

Neurogen receives listing compliance notice letter from NASDAQ

Ligand Pharmaceuticals, Neurogen revise merger agreement

Ligand Pharmaceuticals, Neurogen revise merger agreement

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A can use new treatment option, XYNTHA

Scientists offer first genetic proof of new and rational treatment for osteoporosis

Scientists offer first genetic proof of new and rational treatment for osteoporosis

Receptos raises $25 million through Series A financing

Receptos raises $25 million through Series A financing

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

Cancer-fighting protein successfully placed directly into solid tumors and turned on

Cancer-fighting protein successfully placed directly into solid tumors and turned on

CSHL solves the structure of the zinc-bound ATD domain of the NMDA receptor NR2B subunit

CSHL solves the structure of the zinc-bound ATD domain of the NMDA receptor NR2B subunit

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Neurogen announces financial results for the third quarter of 2009

Neurogen announces financial results for the third quarter of 2009